Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer.

Faucz FR, Horvath A, Rothenbuhler A, Almeida MQ, Libé R, Raffin-Sanson ML, Bertherat J, Carraro DM, Soares FA, Molina Gde C, Campos AH, Alexandre RB, Bendhack ML, Nesterova M, Stratakis CA.

J Clin Endocrinol Metab. 2011 Jan;96(1):E135-40. doi: 10.1210/jc.2010-1655. Epub 2010 Sep 29.

2.

Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors.

Horvath A, Korde L, Greene MH, Libe R, Osorio P, Faucz FR, Raffin-Sanson ML, Tsang KM, Drori-Herishanu L, Patronas Y, Remmers EF, Nikita ME, Moran J, Greene J, Nesterova M, Merino M, Bertherat J, Stratakis CA.

Cancer Res. 2009 Jul 1;69(13):5301-6. doi: 10.1158/0008-5472.CAN-09-0884. Epub 2009 Jun 23.

3.

Analysis of genetic variants of phosphodiesterase 11A in acromegalic patients.

Peverelli E, Ermetici F, Filopanti M, Elli FM, Ronchi CL, Mantovani G, Ferrero S, Bosari S, Beck-Peccoz P, Lania A, Spada A.

Eur J Endocrinol. 2009 Nov;161(5):687-94. doi: 10.1530/EJE-09-0677. Epub 2009 Aug 11.

4.

Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.

Libé R, Fratticci A, Coste J, Tissier F, Horvath A, Ragazzon B, Rene-Corail F, Groussin L, Bertagna X, Raffin-Sanson ML, Stratakis CA, Bertherat J.

Clin Cancer Res. 2008 Jun 15;14(12):4016-24. doi: 10.1158/1078-0432.CCR-08-0106.

5.

Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population.

Horvath A, Giatzakis C, Robinson-White A, Boikos S, Levine E, Griffin K, Stein E, Kamvissi V, Soni P, Bossis I, de Herder W, Carney JA, Bertherat J, Gregersen PK, Remmers EF, Stratakis CA.

Cancer Res. 2006 Dec 15;66(24):11571-5.

6.

Cyclic AMP and c-KIT signaling in familial testicular germ cell tumor predisposition.

Azevedo MF, Horvath A, Bornstein ER, Almeida MQ, Xekouki P, Faucz FR, Gourgari E, Nadella K, Remmers EF, Quezado M, de Alexandre RB, Kratz CP, Nesterova M, Greene MH, Stratakis CA.

J Clin Endocrinol Metab. 2013 Aug;98(8):E1393-400. doi: 10.1210/jc.2012-2838. Epub 2013 Jun 14.

7.

Rare inactivating PDE11A variants associated with testicular germ cell tumors.

Pathak A, Stewart DR, Faucz FR, Xekouki P, Bass S, Vogt A, Zhang X, Boland J, Yeager M, Loud JT, Nathanson KL, McGlynn KA, Stratakis CA, Greene MH, Mirabello L.

Endocr Relat Cancer. 2015 Dec;22(6):909-17. doi: 10.1530/ERC-15-0034.

8.

Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors.

Vezzosi D, Libé R, Baudry C, Rizk-Rabin M, Horvath A, Levy I, René-Corail F, Ragazzon B, Stratakis CA, Vandecasteele G, Bertherat J.

J Clin Endocrinol Metab. 2012 Nov;97(11):E2063-9. doi: 10.1210/jc.2012-2275. Epub 2012 Sep 20.

9.

Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype.

Libé R, Horvath A, Vezzosi D, Fratticci A, Coste J, Perlemoine K, Ragazzon B, Guillaud-Bataille M, Groussin L, Clauser E, Raffin-Sanson ML, Siegel J, Moran J, Drori-Herishanu L, Faucz FR, Lodish M, Nesterova M, Bertagna X, Bertherat J, Stratakis CA.

J Clin Endocrinol Metab. 2011 Jan;96(1):E208-14. doi: 10.1210/jc.2010-1704. Epub 2010 Nov 3.

10.

Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions.

Boikos SA, Horvath A, Heyerdahl S, Stein E, Robinson-White A, Bossis I, Bertherat J, Carney JA, Stratakis CA.

Horm Metab Res. 2008 May;40(5):347-53. doi: 10.1055/s-2008-1076694.

11.

A stop-codon of the phosphodiesterase 11A gene is associated with elevated blood pressure and measures of obesity.

Ohlsson T, Lindgren A, Engström G, Jern C, Melander O.

J Hypertens. 2016 Mar;34(3):445-51; discussion 451. doi: 10.1097/HJH.0000000000000821.

PMID:
26820475
12.

Phosphodiesterase sequence variants may predispose to prostate cancer.

de Alexandre RB, Horvath AD, Szarek E, Manning AD, Leal LF, Kardauke F, Epstein JA, Carraro DM, Soares FA, Apanasovich TV, Stratakis CA, Faucz FR.

Endocr Relat Cancer. 2015 Aug;22(4):519-30. doi: 10.1530/ERC-15-0134. Epub 2015 May 15.

13.
14.

A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia.

Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ, Stein E, Levine E, Delimpasi G, Hsiao HP, Keil M, Heyerdahl S, Matyakhina L, Libè R, Fratticci A, Kirschner LS, Cramer K, Gaillard RC, Bertagna X, Carney JA, Bertherat J, Bossis I, Stratakis CA.

Nat Genet. 2006 Jul;38(7):794-800. Epub 2006 Jun 11.

PMID:
16767104
15.

3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human tissues.

Loughney K, Taylor J, Florio VA.

Int J Impot Res. 2005 Jul-Aug;17(4):320-5.

PMID:
15800651
16.

Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target?

Kelly MP.

Curr Pharm Des. 2015;21(3):389-416. Review.

PMID:
25159071
17.
18.

Expression of PDE11A in normal and malignant human tissues.

D'Andrea MR, Qiu Y, Haynes-Johnson D, Bhattacharjee S, Kraft P, Lundeen S.

J Histochem Cytochem. 2005 Jul;53(7):895-903.

PMID:
15995148
19.

Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD).

Tadjine M, Lampron A, Ouadi L, Horvath A, Stratakis CA, Bourdeau I.

Clin Endocrinol (Oxf). 2008 Sep;69(3):367-73. doi: 10.1111/j.1365-2265.2008.03273.x. Epub 2008 Apr 14.

20.

Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men.

Takahashi H, Lu W, Watanabe M, Katoh T, Furusato M, Tsukino H, Nakao H, Sudo A, Suzuki H, Akakura K, Ikemoto I, Asano K, Ito T, Wakui S, Muto T, Hano H.

Int J Cancer. 2003 Nov 1;107(2):224-8.

Supplemental Content

Support Center